Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 10/10

vs
industry
vs
history
Cash to Debt No Debt
GMED's Cash to Debt is ranked higher than
85% of the 384 Companies
in the Global Medical Devices industry.

( Industry Median: 4.48 vs. GMED: No Debt )
GMED' s 10-Year Cash to Debt Range
Min: No Debt   Max: No Debt
Current: No Debt

Equity to Asset 0.84
GMED's Equity to Asset is ranked higher than
89% of the 367 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. GMED: 0.84 )
GMED' s 10-Year Equity to Asset Range
Min: 0.83   Max: 0.88
Current: 0.84

0.83
0.88
Interest Coverage No Debt
GMED's Interest Coverage is ranked higher than
86% of the 204 Companies
in the Global Medical Devices industry.

( Industry Median: 117.58 vs. GMED: No Debt )
GMED' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 4
Z-Score: 16.24
M-Score: -2.95
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 23.40
GMED's Operating margin (%) is ranked higher than
95% of the 372 Companies
in the Global Medical Devices industry.

( Industry Median: 6.25 vs. GMED: 23.40 )
GMED' s 10-Year Operating margin (%) Range
Min: 23.4   Max: 30.43
Current: 23.4

23.4
30.43
Net-margin (%) 15.79
GMED's Net-margin (%) is ranked higher than
91% of the 372 Companies
in the Global Medical Devices industry.

( Industry Median: 4.71 vs. GMED: 15.79 )
GMED' s 10-Year Net-margin (%) Range
Min: 15.79   Max: 19.13
Current: 15.79

15.79
19.13
ROE (%) 14.53
GMED's ROE (%) is ranked higher than
90% of the 368 Companies
in the Global Medical Devices industry.

( Industry Median: 5.93 vs. GMED: 14.53 )
GMED' s 10-Year ROE (%) Range
Min: 14.53   Max: 21.52
Current: 14.53

14.53
21.52
ROA (%) 12.12
GMED's ROA (%) is ranked higher than
95% of the 382 Companies
in the Global Medical Devices industry.

( Industry Median: 3.43 vs. GMED: 12.12 )
GMED' s 10-Year ROA (%) Range
Min: 12.12   Max: 18.45
Current: 12.12

12.12
18.45
ROC (Joel Greenblatt) (%) 58.40
GMED's ROC (Joel Greenblatt) (%) is ranked higher than
95% of the 381 Companies
in the Global Medical Devices industry.

( Industry Median: 13.35 vs. GMED: 58.40 )
GMED' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 58.4   Max: 69.93
Current: 58.4

58.4
69.93
» GMED's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

GMED Guru Trades in Q2 2013

Paul Tudor Jones 11,700 sh (New)
RS Investment Management 2,118,663 sh (+57.1%)
Ronald Muhlenkamp 96,150 sh (+0.22%)
Joel Greenblatt 10,113 sh (-8.64%)
Chuck Royce 770,677 sh (-10.04%)
Steven Cohen 438,514 sh (-18.29%)
» More
Q3 2013

GMED Guru Trades in Q3 2013

RS Investment Management 2,705,663 sh (+27.71%)
Steven Cohen 543,496 sh (+23.94%)
Paul Tudor Jones 13,300 sh (+13.68%)
Joel Greenblatt Sold Out
Ronald Muhlenkamp 93,805 sh (-2.44%)
Chuck Royce 601,677 sh (-21.93%)
» More
Q4 2013

GMED Guru Trades in Q4 2013

Joel Greenblatt 127,089 sh (New)
Jim Simons 273,600 sh (New)
Steven Cohen 1,016,020 sh (+86.94%)
Paul Tudor Jones 24,700 sh (+85.71%)
Ronald Muhlenkamp 112,875 sh (+20.33%)
Chuck Royce Sold Out
RS Investment Management 2,430,383 sh (-10.17%)
» More
Q1 2014

GMED Guru Trades in Q1 2014

Paul Tudor Jones Sold Out
RS Investment Management 2,407,467 sh (-0.94%)
Joel Greenblatt 107,520 sh (-15.4%)
Jim Simons 181,113 sh (-33.8%)
Ronald Muhlenkamp 51,480 sh (-54.39%)
Steven Cohen 343 sh (-99.97%)
» More
» Details

Insider Trades

Latest Guru Trades with GMED

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ronald Muhlenkamp 2014-03-31 Reduce -54.39%0.22%$19.59 - $26.64 $ 23.02-2%51480
Ronald Muhlenkamp 2013-12-31 Add 20.33%0.07%$17.16 - $19.84 $ 23.0224%112875
Joel Greenblatt 2013-12-31 New Buy0.06%$17.16 - $19.84 $ 23.0224%127089
Joel Greenblatt 2013-09-30 Sold Out 0.01%$16.75 - $18.06 $ 23.0233%0
Ronald Muhlenkamp 2013-03-31 New Buy0.29%$10.49 - $15 $ 23.0272%95935
Joel Greenblatt 2013-03-31 New Buy0.01%$10.49 - $15 $ 23.0272%11069
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 31.00
GMED's P/E(ttm) is ranked higher than
81% of the 413 Companies
in the Global Medical Devices industry.

( Industry Median: 67.60 vs. GMED: 31.00 )
GMED' s 10-Year P/E(ttm) Range
Min: 12.95   Max: 35.54
Current: 31

12.95
35.54
P/B 4.31
GMED's P/B is ranked higher than
63% of the 413 Companies
in the Global Medical Devices industry.

( Industry Median: 3.46 vs. GMED: 4.31 )
GMED' s 10-Year P/B Range
Min: 2.45   Max: 4.94
Current: 4.31

2.45
4.94
P/S 4.90
GMED's P/S is ranked higher than
61% of the 413 Companies
in the Global Medical Devices industry.

( Industry Median: 3.30 vs. GMED: 4.90 )
GMED' s 10-Year P/S Range
Min: 2.48   Max: 5.61
Current: 4.9

2.48
5.61
PFCF 26.77
GMED's PFCF is ranked higher than
86% of the 413 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. GMED: 26.77 )
GMED' s 10-Year PFCF Range
Min: 18.52   Max: 39.26
Current: 26.77

18.52
39.26
EV-to-EBIT 18.00
GMED's EV-to-EBIT is ranked higher than
87% of the 413 Companies
in the Global Medical Devices industry.

( Industry Median: 44.56 vs. GMED: 18.00 )
GMED' s 10-Year EV-to-EBIT Range
Min: 6.7   Max: 21.3
Current: 18

6.7
21.3
Current Ratio 6.36
GMED's Current Ratio is ranked higher than
91% of the 380 Companies
in the Global Medical Devices industry.

( Industry Median: 2.92 vs. GMED: 6.36 )
GMED' s 10-Year Current Ratio Range
Min: 5.97   Max: 10.12
Current: 6.36

5.97
10.12
Quick Ratio 5.36
GMED's Quick Ratio is ranked higher than
89% of the 380 Companies
in the Global Medical Devices industry.

( Industry Median: 2.16 vs. GMED: 5.36 )
GMED' s 10-Year Quick Ratio Range
Min: 4.71   Max: 8.29
Current: 5.36

4.71
8.29

Valuation & Return

vs
industry
vs
history
Price/Net Cash 11.81
GMED's Price/Net Cash is ranked higher than
89% of the 413 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. GMED: 11.81 )
GMED' s 10-Year Price/Net Cash Range
Min: 6.32   Max: 18.33
Current: 11.81

6.32
18.33
Price/Net Current Asset Value 8.08
GMED's Price/Net Current Asset Value is ranked higher than
88% of the 413 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. GMED: 8.08 )
GMED' s 10-Year Price/Net Current Asset Value Range
Min: 4.21   Max: 9.33
Current: 8.08

4.21
9.33
Price/Tangible Book 4.77
GMED's Price/Tangible Book is ranked higher than
69% of the 413 Companies
in the Global Medical Devices industry.

( Industry Median: 5.99 vs. GMED: 4.77 )
GMED' s 10-Year Price/Tangible Book Range
Min: 2.65   Max: 5.51
Current: 4.77

2.65
5.51
Price/Median PS Value 1.22
GMED's Price/Median PS Value is ranked higher than
68% of the 413 Companies
in the Global Medical Devices industry.

( Industry Median: 1.20 vs. GMED: 1.22 )
GMED' s 10-Year Price/Median PS Value Range
Min: 0.63   Max: 1.41
Current: 1.22

0.63
1.41
Price/Graham Number 2.56
GMED's Price/Graham Number is ranked higher than
82% of the 413 Companies
in the Global Medical Devices industry.

( Industry Median: 9.06 vs. GMED: 2.56 )
GMED' s 10-Year Price/Graham Number Range
Min: 1.24   Max: 2.96
Current: 2.56

1.24
2.96
Earnings Yield (Greenblatt) 5.60
GMED's Earnings Yield (Greenblatt) is ranked higher than
78% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 4.90 vs. GMED: 5.60 )
GMED' s 10-Year Earnings Yield (Greenblatt) Range
Min: 4.7   Max: 15
Current: 5.6

4.7
15

Business Description

Industry: Medical Devices » Medical Devices
Compare: » details
Traded in other countries:GM0N.Germany
Globus Medical Inc., was incorporated in Delaware in 2003. The Company is a medical device company focused exclusively on the design, development and commercialization of products that promote healing in patients with spine disorders. It is an engineering-driven company with a history of rapidly developing and commercializing products that assist surgeons in effectively treating their patients, respond to evolving surgeon needs and address new treatment options. All of its products fall into one of two categories: innovative fusion or disruptive technologies. The Company's innovative fusion products address a broad range of spinal fusion surgical procedures. Spinal fusion is a surgical procedure to correct problems with the individual vertebrae, the interlocking bones making up the spine, by preventing movement of the affected bones. These advantages have enabled it to grow its sales at a faster rate than the broader spine industry. It defines disruptive technologies as those that represent a significant shift in the treatment of spine disorders by allowing for novel surgical procedures, improvements to existing surgical procedures, and the treatment of spine disorders by new physician specialties, and surgical intervention earlier in the continuum of care. The Company's comprehensive REVERE pedicle screw and rod system incorporates a convenient non-threaded locking cap design that eases building of thoracolumbar fixation constructs to readily adapt to the patient's anatomy and condition, for a range of clinical applications. Certain other of its products are first-in-class, such as its XPAND and FORTIFY corpectomy devices that incorporate smooth expansion capability, have a range of size options for optimal fit, and are manufactured from radiolucent polyetheretherketone, or PEEK, to allow for postoperative radiographic visualization. Certain of its other products, such as COALITION and INDEPENDENCE stand-alone interbody fusion devices, simplify the surgical technique by reducing steps and hardware while providing confident stabilization. Its significant competitors are Medtronic, DePuy (a division of Johnson & Johnson), Synthes (which is being acquired by Johnson & Johnson), Stryker and NuVasive, which together represent a significant portion of the spine market.
» More Articles for GMED

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
NYSE stocks posting largest volume increases Jul 25 2014
Globus Medical Schedules Second Quarter 2014 Earnings Release and Conference Call Jul 15 2014
GLOBUS MEDICAL INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 11 2014
Cyberonics Shocks Investors With Weak Profit Guidance Jun 04 2014
Globus Medical Launches MONUMENT Anterior Spondylolisthesis Reduction System May 29 2014
Globus Medical to Participate at Investor Events in June May 27 2014
Globus Medical to Present at the Bank of America Merrill Lynch 2014 Healthcare Conference May 07 2014
GLOBUS MEDICAL INC Financials May 07 2014
GLOBUS MEDICAL INC Files SEC form 10-Q, Quarterly Report Apr 30 2014
Globus Medical well positioned for revenue growth, says Canaccord Apr 30 2014
GMED's CEO Discusses Q1 2014 Results - Earnings Call Transcript Apr 29 2014
Globus Medical Inc Earnings Call scheduled for 5:30 pm ET today Apr 29 2014
GLOBUS MEDICAL INC Files SEC form 8-K, Results of Operations and Financial Condition Apr 29 2014
Globus Medical Reports 2014 First Quarter Results Apr 29 2014
Q1 2014 Globus Medical Inc Earnings Release - After Market Close Apr 29 2014
Globus Medical Schedules First Quarter 2014 Earnings Release and Conference Call Apr 10 2014
Why the Earnings Streak Will Continue for Globus Medical (GMED) Mar 19 2014
Wall Street Transcript Interview with Brian Roberts, the CFO of Insulet Corporation (PODD) Mar 17 2014
A Wall Street Transcript Interview with Matt Miksic, a Managing Director and Senior Research Analyst... Mar 17 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide